These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 18327722)

  • 1. Joint one-sided and two-sided simultaneous confidence intervals.
    Braat S; Gerhard D; Hothorn LA
    J Biopharm Stat; 2008; 18(2):293-306. PubMed ID: 18327722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
    Wardley AM
    Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy.
    Akashi-Tanaka S; Omatsu M; Shimizu C; Ando M; Terada K; Shien T; Kinoshita T; Fujiwara Y; Seki K; Hasegawa T; Fukutomi T
    Breast; 2007 Oct; 16(5):482-8. PubMed ID: 17418576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant endocrine therapy in postmenopausal breast cancer patients.
    Köberle D; Thürlimann B
    Breast; 2005 Dec; 14(6):446-51. PubMed ID: 16169728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial.
    Ingle JN; Tu D; Pater JL; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Goss PE
    Breast Cancer Res Treat; 2006 Oct; 99(3):295-300. PubMed ID: 16541302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anastrozole: new indication. Adjuvant treatment of non metastatic breast cancer: useful for some patients.
    Prescrire Int; 2005 Apr; 14(76):43-4. PubMed ID: 15875334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
    Kaufmann M; Rody A
    Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):146-54. PubMed ID: 16621229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regression of chronic lymphocytic leukemia with aromatase inhibitor-letrozole?
    Paydas S
    Leuk Res; 2009 Apr; 33(4):566-7. PubMed ID: 18585780
    [No Abstract]   [Full Text] [Related]  

  • 9. The differences in outcome between ATAC and BIG 1-98 suggest efficacy differences between these two nonsteroidal AIs.
    Mouridsen HT
    Cancer Invest; 2010; 28 Suppl 1():1-3. PubMed ID: 20653402
    [No Abstract]   [Full Text] [Related]  

  • 10. Meta-analysis of pre-operative aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor-positive breast cancer.
    Seo JH; Kim YH; Kim JS
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):261-6. PubMed ID: 18365197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.
    Boccardo F; Rubagotti A; Conti G; Potenzoni D; Manganelli A; Del Monaco D
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):415-20. PubMed ID: 15838655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant endocrine treatment of early breast cancer.
    Lønning PE
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):223-38. PubMed ID: 17512446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial.
    Nicolini A; Carpi A
    Biomed Pharmacother; 2005 Jun; 59(5):253-63. PubMed ID: 15913946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormonal therapy for postmenopausal breast cancer: the science of sequencing.
    Miller WR; Bartlett JM; Canney P; Verrill M
    Breast Cancer Res Treat; 2007 Jun; 103(2):149-60. PubMed ID: 17039263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Test for the consistency of noninferiority from multiple clinical trials.
    Yan X; Wang MC; Su X
    J Biopharm Stat; 2007; 17(2):265-78. PubMed ID: 17365223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of the development of letrozole and its use in advanced breast cancer and in the neoadjuvant setting.
    Bhatnagar AS
    Breast; 2006 Feb; 15 Suppl 1():S3-13. PubMed ID: 16500235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant hormone therapy for breast cancer: alternatives to tamoxifen.
    Prescrire Int; 2005 Jun; 14(77):108-10. PubMed ID: 15984106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An alternative approach to assess exchangeability of a test treatment and the standard treatment with normally distributed response.
    Tsong Y; Shen M
    J Biopharm Stat; 2007; 17(2):329-38. PubMed ID: 17365227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
    N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolving role of letrozole in the adjuvant setting: first results from the large, phase III, randomized trial BIG 1-98.
    Monnier A
    Breast; 2006 Feb; 15 Suppl 1():S21-9. PubMed ID: 16500237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.